Onkologie, Hämatologie - Daten und Informationen

4 Protektive Medikamente (Organprotektoren): Literatur

Autor/en: J. Büntzel, F. Bruns, D. Lüftner, D. Pollmann, S. Schildhauer
Letzte Änderung: 25.01.2006
  • Antonadou D, Coliarakis N, Synodinou M, Athanassiou H, Konveli A, Verigos C, Georgakopoulos G, Panoussaki K, Karageorgis P, Throuvalas N.
    Clinical Radiation Oncology Hellenic Group: Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer.
    Int J Radiat Oncol Biol Phys 2001;51:915-922. PM:11704311

  • Bates M, Lieu D, Zagari M, Spiers A, Williamson T.
    A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer.
    Clin Ther 1997;19:167-84. PM:9182022

  • Bohuslavizki KH, Klutmann S, Brenner W, Mester J, Hentze E, Claussen M.
    Salivary gland protection by amifostine in high-dose radioiodine therapy: results of a double-blind placebo-controlled study.
    J Clin Oncol 1998;16:3542-3549. PM:9817273

  • Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R.
    Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
    J Clin Oncol 2000;18:3339-3345. PM:11013273

  • Budd GT, Ganapathi G, Bukowski RM, Murphy S.
    Clinical effects of amifostine (Ethyol) in patients treated with carboplatin.
    Eur J Cancer 1996;3:43-45. PM:8976822

  • Büntzel J, Bokemeyer C.
    Klinische Anwendung von Zytoprotektiva.
    Im Focus Onkologie 2000;6:66-69.

  • Büntzel J, Küttner K, Fröhlich D, Glatzel M.
    Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer.
    Ann Oncol 1998;9:505-509. PM:9653491

  • Büntzel J, Micke O, Glatzel M.
    Amifostine in radiochemotherapy of head and neck cancer - preliminary results of the placebo-controlled trial.
    Support Care Cancer 2003;11:388. PM:16243440

  • Fukuoka M, Negoro S, Masuda N, Furuse K, Kawahara M, Kodama N, Ikegami H, Nakamura S, Nishio H, Ohnoshi T.
    Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamid-induced urinary disorders.
    Cancer Res Clin Oncol 1991;117:473-478. PM:1909700

  • Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, Zee B, Blackstein M, Tomiak E, Yan J, Batist G, Fisher B, Iglesias J.
    Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer.
    J Clin Oncol 1999;17:3038-3047. PM:10506598

  • Gennari A, Salvadori B, Donati S.
    Cardiotoxicity of epirubicin/paclitaxel-containing regimens: Role of cardiac risk factors.
    J Clin Oncol 1999;18:3115-3124. PM:10550159

  • Gold MA, Walker JL, Berek JS, Hallum AV 3rd, Garcia DJ, Alberts DS.
    Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies.
    Gynecol Oncol 2003;90:325-330. PM:12893194

  • Goren MP, Anthony LP, Hande KR, Johnson DH, Brade WP, Frazier MW, Bush DA, Li JT.
    Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide.
    J Clin Oncol 1998;16:616-621. PM:9469350

  • Hartmann JT, von Vangerow A, Fels LM, Knop S, Stolte H, Kanz L, Bokemeyer C.
    A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
    Br J Cancer 2001;84:313-320. PM:11161394

  • Hasinoff BB.
    Chemistry of dexrazoxane and analogues.
    Semin Oncol 1998;25:3-9. PM:9768817

  • Hellmann K.
    Overview and historical development of dexrazoxane.
    Semin Oncol 1998;25:48-54. PM:9768824

  • Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, Gradishar WJ, Green DM, Langdon RJ Jr, Mitchell RB, Negrin R, Szatrowski TP, Thigpen JT, Von Hoff D, Wasserman TH, Winer EP, Pfister DG.
    American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
    J Clin Oncol 1999;17:3333-3355. PM:10506637

  • Herman EH, Ferrans VJ, Jordan W.
    Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits.
    Res Commun Chem Pathol Pharmacol 1981;31:85-97. PM:6790165

  • Johnson PW, Muers MF, Peake MD, Poulter KM, Gurney EM, Napp VV, Hepburn PM, Brown JM.
    A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small-cell lung cancer.
    Br J Cancer 2001;84:19-24. PM:11139307

  • Katz A, Epelman S, Anelli A.
    A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: Sustained efficiency and simplified administration.
    J Cancer Res Clin Oncol 1995;121:128-131. PM:7883776

  • Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Hamesley H, Belpomme D, Glick J.
    Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer.
    J Clin Oncol 1996;14:2101-2112. PM:8683243

  • Leong SS, Tan EH, Fong KW, Wilder-Smith E, Ong YK, Tai BC, Chew L, Lim SH, Wee J, Lee KM, Foo KF, Ang P, Ang PT.
    Randomized double-blind trial of combined modality treatment with or without amifostine in unresetable stage III non-small-cell lung cancer.
    J Clin Oncol 2003;21:1767-1774. PM:12721253

  • Liu T, Liu Y, He S, Zhang Z, Kligerman MM.
    Use of radiation with or without WR-2721 in advanced rectal cancer.
    Cancer 1992;69:2820-2825. PM:1315211

  • Lopez M, Vici P, Di Lauro K, Conti F, Paoletti G, Ferraironi A, Sciuto R, Giannarelli D, Maini CL.
    Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.
    J Clin Oncol 1998;16:86-92. PM:9440727

  • Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione L, Di Vagno G, Ferrau‘ F, Scambia G.
    Multicenter Italian Trials in Ovarian Cancer Investigators: Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.
    Ann Oncol 2003;14:1086-1093. PM:12853351

  • Mace JR, Keohan ML, Bernardy H, Junge K, Niebch G, Romeis P, Thoma A, Wagner T, Mueller U, Demetri G, Baker LH.
    Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
    Clin Cancer Res 2003;9:5829-5834. PM:14676103

  • McDonald S, Meyerowitz C, Smudzin T, Rubin P.
    Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction.
    Int J Radiat Oncol Biol Phys 1994;29:747-754. PM:8040020

  • Ormstad K, Orrenius S, Lastbom T, Uehara N, Pohl J, Stekar J, Brock N. Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat.
    Cancer Res 1983;43:333-338. PM:6401168

  • Patt HM, Tyree EB, Straube RL.
    Cystein protection against X-irradiation.
    Science 1949;110:213-214.

  • Phillips TL, Yuhas JM, Wasserman TH.
    Differential protection against alkylating agent injury in tumors and normal tissues.
    In: Annonymus (ed) Radioprotectors and Anticarcinogens.
    Academic Press 1993;735-748.

  • Poplin EA, LoRusso P, Lokich JJ, Gullo JJ, Leming PD, Schulz JJ, Veach SR, Mc Culloch W, Baker L Schein P.
    Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer.
    Cancer Chemother Pharmacol 1994;33:415-419. PM:8306416

  • Schiller JH, Storer B, Berlin J, Wittenkeller J, Larson M, Pharo L, Berry W.
    Amifostine, cisplatin, and vinblastin in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival.
    J Clin Oncol 1996;14:1913-1921. PM:8656260

  • Schroeder PE, Jensen PB, Sehested M, Hofland KF, Langer SW, Hasinoff BB.
    Metabolism of Dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide.
    Cancer Chemother Pharmacol 2003;52:167-174. PM:12750840

  • Schuchter LM, Hensley ML, Meropol NJ, Winer EP.
    American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel. 2002 update of recommendations for use of the chemotherapy and radiotherapy protectants. Clinical Practice Guidelines of the American Society of Clinical Oncology.
    J Clin Oncol 2002;20:2895-2903. PM:12065567

  • Shaw LM, Bonner HS, Brown DQ.
    Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.
    Drug Metab Dispos 1994;22:894-902. PM:7895607

  • Shaw LM, Bonner H, Lieberman R.
    Pharmacokinetic profile of amifostine.
    Semin Oncol 1996;23:18-22. PM:8783662

  • Shaw LM, Bonner H, Schuchter L, Schiller JH, Nakashima H, Lieberman R.
    Population pharmacokinetics (PK) of amifostine (AMI) in cancer patients.
    Proc ASCO 1996;15:478.

  • Sparano JA, Speyer J, Gradishar WJ, Liebes L, Sridhara R, Mendoz Fry D, Egorin MJ.
    Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer.
    J Clin Oncol 1999;17:880-886. PM:10071279

  • Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin Ferrans V, Stecy P, Zeleniuch-Jacquotte A.
    Protective effect of the bisperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advance breast cancer.
    N Engl J Med 1988;319:745-752. PM:3137469

  • Swain SM.
    Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
    Semin Oncol 1998;25:43-47. PM:9768823

  • Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA.
    Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
    J Clin Oncol 1997;15:1318-1332. PM:9193323

  • Tetef ML, Synold TW, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G, Yen Y, Groshen S, Johnson K, Lenz HJ, Gandara D, Doroshow JH.
    Phase I trial of 96-hour continous infusion of dexrazoxane in patients with advanced malignancies.
    Clin Cancer Res 2001;7:1569-1576. PM:11410492

  • Vacha P, Fehlauer F, Mahlmann B, Marx M, Hinke A, Sommer K, Richter E, Feyerabend T.
    Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer.Is there evidence for radioprotection?
    Strahlenther Onkol 2003;179:385-389. PM:12789464

  • Venturini M, Michelotti A, Del Mastro L, Gallo L, Carnino F, Garrone O, Tibaldi C, Molea N, Bellina RC, Pronzato P, Cyrus P, Vinke J, Testore F, Guelfi M, Lionetto R, Bruzzi P, Conte PF, Rosso R.
    Multicenter randomized controlled clinical trial to evaluate cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
    J Clin Oncol 1996;14:3112-3120. PM:8955656

  • Verhoef V.
    Effect of ADR-529 (ICRF-187) on the antitumor activity of doxorubicin in mouse models of murine and human cancer.
    Dublin, OH, Adria Labs Internal Report 1987;87-08:73.

  • Vieira MM, Brito GA, Bilarmino-Filho JN, Macedo FY, Nery KA, Cunha FQ, Ribeiro RA.
    Use of dexamthasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.
    Int J Urol 2003;10:595-602. PM:14633084

  • Wexler LH, Andrich MP, Venzon D, Berg SL, Weaver-McClure L, Chen CC, Dilsizian V, Avila N, Jarosinski P, Balis FM, Poplack DG, Horowitz ME.
    Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.
    J Clin Oncol 1996;14:362-372. PM:8636745

  • Yuhas JM, Spellman JM, Culo F.
    The role of WR-2721 in radiotherapy and/or chemotherapy.
    Cancer Clin Trials 1980;3:211-216. PM:6254681

Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag"
Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag